Verismo Therapeutics SynKIR-110 Shows Promising Safety Profile in Phase 1 STAR-101 Trial for Advanced Solid Tumors

Key Takeaways

• SynKIR-110 showed favorable safety profile with no dose-limiting toxicities across initial dose cohorts in advanced solid tumor patients
• Preliminary data indicate dose-dependent efficacy signals and increased cell persistence at higher dose levels
• Dose escalation continues in the STAR-101 Phase 1 trial to determine recommended Phase 2 dose

---

Verismo Therapeutics announced promising initial clinical data from its STAR-101 Phase 1 trial of SynKIR-110, a novel KIR-CAR therapy for advanced solid tumors, presented at the AACR 2026 Plenary Session on April 20, 2026.

The early clinical results demonstrate a favorable safety profile across the first three dose level cohorts, with no dose-limiting toxicities observed. This milestone allows the company to continue dose escalation to determine the optimal Phase 2 dose for this potentially first-in-class multi-chain KIR-CAR living medicine.

Clinical Results Show Promise

Preliminary data from the STAR-101 trial revealed dose-dependent efficacy signals, suggesting that higher doses of SynKIR-110 may provide enhanced therapeutic benefit. The therapy also demonstrated on-tumor target biologic activity with increased cell persistence at elevated dose levels, indicating the treatment’s ability to maintain therapeutic presence where needed.

SynKIR-110 represents a novel approach to cancer immunotherapy, utilizing KIR-CAR (Killer Immunoglobulin-like Receptor Chimeric Antigen Receptor) technology to potentially overcome limitations of traditional CAR-T therapies in solid tumors.

Market Implications

The positive safety profile and early efficacy signals position Verismo Therapeutics competitively in the expanding CAR-T therapy market, particularly for solid tumors where treatment options remain limited. The company’s multi-chain KIR-CAR platform could differentiate it from existing immunotherapies.

Next Steps

Verismo plans to continue dose escalation in the ongoing Phase 1 trial to establish the recommended Phase 2 dose. The company will likely provide updated data at future medical conferences as enrollment progresses and more patients reach evaluable timepoints.

The STAR-101 trial’s progression without dose-limiting toxicities represents a significant milestone for both Verismo and patients with advanced solid tumors who have limited treatment options.

---

Frequently Asked Questions

What does this mean for patients with advanced solid tumors?

The positive safety data and early efficacy signals suggest SynKIR-110 could become a new treatment option for patients with advanced solid tumors, though the therapy is still in early-stage testing and not yet available outside clinical trials.

When will SynKIR-110 be available to patients?

SynKIR-110 is currently in Phase 1 trials. If successful, it would need to complete Phase 2 and Phase 3 trials before potential FDA approval, which typically takes several years.

How does SynKIR-110 differ from existing CAR-T therapies?

SynKIR-110 uses multi-chain KIR-CAR technology designed specifically for solid tumors, potentially overcoming challenges that traditional CAR-T therapies face in treating solid cancers compared to blood cancers.